These findings indicate an important mechanism of dsRNA-mediated innate immune sensitivity in ATRX-deficient gliomas, distinct from the effects of ATRX loss on dsDNA-mediated immune suppression noted in previous studies. The gene discussed is ATRX; the disease is central nervous system cancer.